531739

Gennex Lab. financials

Market cap
₹268 Cr
Sector
Healthcare

What Gennex Lab. does

Gennex Laboratories Limited manufactures Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates at its factory in IDA Bollaram, Jinnaram Mandal, Sangareddy district, Telangana. The company holds ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 certifications from TUV NORD Cert GmbH and a GMP & WHO-GMP certification from the State Drug Licensing authority. It has also been awarded European Union Written Confirmation (EU-WC) by the CDSCO for the APIs Guaifenesin, Methocarbamol and Phenazopyridine Hcl, permitting their sale into EU-regulated markets. Management has stated it is working to add further APIs to its manufacturing range by expanding production capacity and R&D efforts.

Segments

  • Active Pharmaceutical Ingredients (APIs) & Intermediates manufacturing
Manufacturing facility
1 (IDA Bollaram, Sangareddy district, Telangana)
Permanent employees
115
EU Written Confirmation (EU-WC) approved APIs
3 (Guaifenesin, Methocarbamol, Phenazopyridine Hcl)
Quality certifications
ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, WHO-GMP
Founded 1990Headquarters Hyderabad, TelanganaEmployees 115 (FY25) Company website

Quarterly results

Q1 FY27: revenue up 16.6%, net profit down 6.8% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue33 40 40 34 39 +18%43 +7%61 +51%40 +17%
EBITDA7 7 2 5 8 +1%9 +20%6 +192%4 −14%
Net profit5 5 3 5 6 +2%6 +19%4 +45%5 −7%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Performance −3.1% 1Y

₹8.0₹10.0₹12.0₹14.0₹16.0Sept 25Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26

1Y: ₹11.45 on 10 Sept 2025 → ₹11.1. High ₹17.02 (28 Oct 2025), low ₹7.13 (30 Mar 2026).

Financials, as filed

Revenue grew 36.6% a year over 3 years, FY23 to FY26. Operating margin widened to 15.3%.

Year endingFY23FY24FY25FY26
Revenue₹70 Cr₹92 Cr₹142 Cr₹177 Cr
Operating profit₹9 Cr₹22 Cr₹21 Cr₹27 Cr
Operating margin12.4%23.9%14.7%15.3%
Interest₹1 Cr₹3 Cr₹3 Cr₹4 Cr
Depreciation₹1 Cr₹2 Cr₹3 Cr₹3 Cr
Net profit₹5 Cr₹13 Cr₹18 Cr₹21 Cr
Net margin7.1%14.4%12.8%11.8%
Cash from operations₹24 Cr₹-47 Cr₹-11 Cr₹-64 Cr
Free cash flow₹-16 Cr₹-31 Cr₹-20 Cr₹-76 Cr
ROCE11.0%14.0%13.0%11.0%
How to read this

From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.

Balance sheet

Year endingFY21FY22FY23FY24FY25FY26
Equity capital₹13 Cr₹13 Cr₹18 Cr₹23 Cr₹24 Cr₹24 Cr
Reserves₹27 Cr₹31 Cr₹62 Cr₹148 Cr₹189 Cr₹198 Cr
Borrowings₹7 Cr₹10 Cr₹1 Cr₹6 Cr₹88 Cr₹79 Cr
Other liabilities₹12 Cr₹14 Cr₹51 Cr₹54 Cr₹55 Cr₹47 Cr
Total liabilities₹59 Cr₹68 Cr₹132 Cr₹230 Cr₹357 Cr₹349 Cr
Fixed assets₹14 Cr₹14 Cr₹74 Cr₹56 Cr₹76 Cr₹61 Cr
Capital work in progress₹0 Cr₹0 Cr₹0 Cr₹2 Cr₹0 Cr₹13 Cr
Investments₹7 Cr₹7 Cr₹0 Cr₹0 Cr₹0 Cr₹0 Cr
Other assets₹38 Cr₹48 Cr₹59 Cr₹172 Cr₹281 Cr₹275 Cr
Total assets₹59 Cr₹68 Cr₹132 Cr₹230 Cr₹357 Cr₹349 Cr
How to read this

As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.

Who owns it

As disclosed at Jun 2026

Since Jun 2025, promoters added +3.81 pp while the public trimmed −3.79 pp. The shareholder count shrank 9% to 82,886.

Promoters
23.6%
Public
76.4%

Since Jun 2025

  • Promoters +3.81 pp
  • Public −3.79 pp

How it drifted, 12 quarters

Sep '23Dec '24Jun '26

Ownership split by quarter, oldest first. Sep '23: Promoters 23.6%, Public 76.4%.Dec '23: Promoters 23.6%, Public 76.4%.Mar '24: Promoters 18.4%, Public 81.6%.Jun '24: Promoters 18.4%, Public 81.6%.Sep '24: Promoters 18.4%, Public 81.6%.Dec '24: Promoters 18.4%, Public 81.6%.Mar '25: Promoters 18.4%, Public 81.6%.Jun '25: Promoters 19.8%, Public 80.2%.Sep '25: Promoters 23.6%, Public 76.4%.Dec '25: Promoters 23.6%, Public 76.4%.Mar '26: Promoters 23.6%, Public 76.4%.Jun '26: Promoters 23.6%, Public 76.4%.

Who was buying across the market this quarter →

Who bought this quarter

since Mar 2026

Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.

The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.

Who is on the register

Named in the Jun 2026 filing

Every holder of Gennex Lab. above SEBI's 1% disclosure line, and what changed since Mar 2026.

HolderStakeChange
Premier Fiscal Services Private Limited 21.83%unchanged
Jms Mines & Minerals Private Limited 3.25%unchanged
Anupriya Consultants Pvt Ltd 1.84%newly disclosed
Dorite Tracon Private Limited 1.56%−0.33 pp
Sanjay Kumar 1.53%unchanged
Vab Ventures Limited 1.42%unchanged
Rajababu Sampatrao Bandela 1.41%unchanged
Subhash Chand Bhura Trusteeof Anuj Bhura Welfare Trust 0.32%unchanged
Prudential Investment Limited 0.02%unchanged
Vinod Baid 0.02%unchanged
India Securities Brooking Private Limited 0.02%unchanged
Gopalakrishnan Muralidharan Tiruvarur 0.00%unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

What the price assumes

Attractive

To justify its price of ₹11, this stock must grow earnings at 5% every year for 7 years. Our analysis caps realistic growth at ~62%. At that growth it is worth ₹171 — upside of 1443%.

Growth the price implies
5.1% a year
for 7 years, fading to 4%
It has actually compounded at
62.2% a year
net profit, FY23–FY26
The gap
-0.6 pp
1443% downside if it only repeats history
Price today ₹11.1 Value at the reference growth ₹171.3

Change the assumptions yourself →

Learn to analyse Gennex Lab.

Guides on how to read this kind of business and the numbers that matter.